David A. Siegel Biotechnology

Two Sigma Advisers, LP

$46.1 Billion
Q2 2025

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade
ALDX Aldeyra Therapeutics, Inc.	$313M	$117,000 0.0% of portfolio	30,800	Q2 2025 Reduced 6.95%
CDXS Codexis, Inc.	$187M	$112,000 0.0% of portfolio	46,000	Q2 2025 Reduced 53.77%
REPL Replimune Group, Inc.	$259M	$103,000 0.0% of portfolio	11,100	Q2 2025 Reduced 43.37%
TNYA Tenaya Therapeutics, Inc.	$31.4M	$102,000 0.0% of portfolio	167,800	Q2 2025 Added 223.94%
APLT Applied Therapeutics Inc.	$21.1M	$94,000 0.0% of portfolio	303,900	Q2 2025 Reduced 53.84%
IGMS Igm Biosciences, Inc.	$37.7M	$92,000 0.0% of portfolio	82,700	Q2 2025 Reduced 8.62%
INZY Inozyme Pharma, Inc.	$161M	$68,000 0.0% of portfolio	17,000	Q2 2025 Reduced 80.77%
ATAI Atai Life Sciences N.V.	$685M	$67,000 0.0% of portfolio	30,900	Q2 2025 New
GBIO Generation Bio Co.	$239M	$61,000 0.0% of portfolio	191,400	Q2 2025 Reduced 1.34%
HOWL Werewolf Therapeutics, Inc.	$35.4M	$61,000 0.0% of portfolio	56,600	Q2 2025 Reduced 26.49%
ACIU Ac Immune Sa	$179M	$58,000 0.0% of portfolio	28,810	Q2 2025 Added 22.02%
XBIT X Biotech Inc.	$90.4M	$48,000 0.0% of portfolio	16,300	Q2 2025 Reduced 6.32%
STRO Sutro Biopharma, Inc.	$40.7M	$47,000 0.0% of portfolio	66,300	Q2 2025 Reduced 72.48%
ATHA Athira Pharma, Inc.	$14.4M	$46,000 0.0% of portfolio	154,200	Q2 2025 Reduced 1.85%
ABUS Arbutus Biopharma Corp	$510M	$42,000 0.0% of portfolio	13,900	Q2 2025 Added 15.83%
ELEV Elevation Oncology, Inc.	$8.39M	$39,000 0.0% of portfolio	107,400	Q2 2025 Reduced 44.38%
RPTX Repare Therapeutics Inc.	$65.4M	$38,000 0.0% of portfolio	27,700	Q2 2025 New
RLYB Rallybio Corp	$16.1M	$30,000 0.0% of portfolio	88,900	Q2 2025 Reduced 2.33%
ATOS Atossa Therapeutics, Inc.	$97.5M	$28,000 0.0% of portfolio	34,200	Q2 2025 Reduced 39.89%
RLMD Relmada Therapeutics, Inc.	$16.9M	$15,000 0.0% of portfolio	25,100	Q2 2025 Reduced 91.28%
LCTX Lineage Cell Therapeutics, Inc.	$171M	$13,000 0.0% of portfolio	14,500	Q2 2025 Reduced 93.51%
STTK Shattuck Labs, Inc.	$32.2M	$11,000 0.0% of portfolio	14,000	Q2 2025 Reduced 83.93%
BCAB Bio Atla, Inc.	$13.4M	$5,000 0.0% of portfolio	14,100	Q2 2025 Reduced 92.54%
ADAP Adaptimmune Therapeutics PLC	$13.1M	$3,000 0.0% of portfolio	13,304	Q2 2025 Reduced 93.56%
SBTX Silverback Therapeutics, Inc.	$0	$0 0.0% of portfolio	41,200	Q2 2025 Added 0.73%

Shares Options

David A. Siegel

David A. Siegel is the co-founder and CEO of Two Sigma Advisers, a successful investment firm that uses technology and data-driven approaches to investing. Siegel is known for his expertise in quantitative investing and his innovative approach to investing. He has generated strong returns for his clients over the long term.

Track David A. Siegel's portfolio

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account